- Record: found
- Abstract: not found
- Article: not found
Population Pharmacokinetics of MCLA-128, a HER2/HER3 Bispecific Monoclonal Antibody, in Patients with Solid Tumors
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
MCLA-128 is a bispecific monoclonal antibody targeting the HER2 and HER3 receptors
and is in development to overcome HER3-mediated resistance to anti-HER2 therapies.
The aims of this analysis were to characterize the population pharmacokinetics of
MCLA-128 in patients with various solid tumors, to evaluate patient-related factors
that affect the disposition of MCLA-128, and to assess whether flat dosing is appropriate.